{
  "url": "https://www.law.cornell.edu/regulations/new-york/10-NYCRR-405.30",
  "title": "N.Y. Comp. Codes R. & Regs. Tit. 10 ยง 405.30 - Organ and vascularized composite allograft transplant services/programs",
  "content": "N.Y. Comp. Codes R. & Regs. Tit. 10 ยง 405.30 - Organ and vascularized composite allograft transplant services/programs\n\nState Regulations\n(a) Definitions. For purposes of this section the following shall have the\nfollowing meanings: (1)\n\nDepartment\nshall mean the New York State Department of\n\nHealth. (2)\n\nLiving\ndonor\nis an individual who donates an organ or a vascularized\ncomposite allograft while alive. (3)\n\nOrgan\nmeans a human\nkidney, heart, liver, lung, pancreas, uterus, stomach, intestine, and/or any\nother tissue requiring revascularization or immunosuppression in the\nrecipient. (4)\n\nOrgan\nprocurement organization (OPO)\nmeans a facility or institution engaged\nin procuring organs and/or vascularized composite allografts for\ntransplantation, or therapy purposes but does not include: (i) facilities or institutions which permit\nprocurement activities to be conducted on their premises by employees or agents\nof an approved organ procurement organization; or\n(ii)\nfacilities or consortia of facilities\nwhich conduct transplantation activities in accordance with article 28 of the\n\nPublic Health Law when the organ is procured through an approved organ\nprocurement organization, or from a living donor. (5)\n\nOrgan trafficking\nis the\nrecruitment, transport, transfer, harboring or receipt of living or deceased\npersons or their organs by means of the threat or use of force or other forms\nof coercion, of abduction, of fraud, of deception, of the abuse of power or of\na position of vulnerability, or of the giving to, or the receiving by, a third\nparty of payments or benefits to achieve the transfer of control over the\npotential donor, for the purpose of exploitation by the removal of organs for\ntransplantation. (6)\n\nPatient\nmeans either the living donor or the recipient: (i) adult\nmeans a patient 18\nyears of age or older at the time of the transplant; (ii)\npediatric patient\nmeans\na patient who has not reached his or her 18th birthday at the time of the\ntransplant. (7)\n\nQualified mental health professional\nshall mean a\npsychiatrist, psychologist, or qualified social worker assigned to evaluate the\npotential recipient and/ or living donor. (8)\n\nQualified social worker\nshall mean a person who is licensed and registered by the State Education\n\nDepartment to practice as a licensed master social worker (LMSW) or licensed\nclinical social worker (LCSW), within the scope of practice defined in article\n154 of the Education Law. (9)\n\nRecipient\nis an individual who receives transplanted organs, or a vascularized composite allograft. (10)\n\nTransplant center\nmeans\na unit within a hospital that performs transplants, including but not limited\nto activities such as qualifying patients for transplant, registering patients\non the national wait list, performing transplant surgery and providing care\nbefore and after transplant. A transplant center may include one or more\ntransplant programs. (11)\n\nTransplant commercialism\nis a policy or practice in which an\norgan is treated as a commodity, including being bought, sold, or used for\nmaterial gain. (12)\n\nTransplant program\nmeans the persons or entity that provides\norgan specific transplant services within a transplant center. (13)\n\nTransplant services\nmeans the provision of organ, living donor and or vascularized composite\nallograft transplants and other medical and surgical specialty services\nrequired for the care of transplant recipients and living donors. (14)\n\nTransplant tourism\nis\ntravel for transplant that involves organ trafficking and/or transplant\ncommercialism. (15)\n\nTravel\nfor transplant\nis the movement of organs, vascularized composite\nallografts, donors, recipients, or transplant professionals who travel across\nnational borders for transplant purposes. (16)\n\nVascularized composite\nallograft\nmeans a contiguous segment of mixed allogeneic tissues whose\nrelationships have been altered only at the segment boundaries and whose\ntransplantation requires revascularization and/or immunosuppression in the\nrecipient. Vascularized composite allografts include, but are not limited to, hand, face, and other such contiguous segments. (b) General requirements. Hospitals shall not admit patients for, or otherwise\nprovide, transplantation services unless the hospital is specifically approved\nby the department to provide transplant services. Transplant services for\npediatric patients shall only be provided in a hospital approved by the\ndepartment to provide transplant services. Hospitals that provide pediatric\ntransplant services must comply with section\n405.22\n(a) of this\n\nPart and must develop and adhere to written policies and procedures specific to\npediatric patients. In addition, the following standards apply to all\ntransplant centers and programs: (1)\n\nTransplant services, or any new Institutional Review Board (IRB) approved\nmedical/surgical treatments which involve transplant medical/surgical care\nincluding but not limited to transplant immunology, shall be performed only in\nhospitals approved by the department to perform such transplant\nservices. (2)\n\nThe hospital shall be\na member in good standing of the Organ and Procurement and Transplantation\n\nNetwork (OPTN) approved by the Secretary of the U.S. Department of Health and\n\nHuman Services (HHS) and shall abide by its rules and requirements. (3)\n\nWhen fully operational, to ensure quality\nof care, the hospital shall perform at least 10 liver transplants per year if\nit is to continue as an approved liver transplant program; or at least 10 human\nheart transplants per year if it is to continue as an approved heart transplant\nprogram; or at least 10 kidney transplants a year if it is to continue as an\napproved kidney transplant program; or at least 10 lung transplants per year if\nit is to continue as an approved lung transplant program. The department will\nmonitor outcomes for graft and patient survival. (4)\n\nThe hospital shall participate in a\npatient registry program with an organ procurement organization designated by\nthe Secretary of the U. S. Department of Health and Human Services. Before\narranging for the placement of the patient on the waiting list, each facility\nshall inform a patient awaiting transplantation of the prohibition against\nbeing placed on multiple facility waiting lists within New York State before\narranging for the placement of the patient on the waiting list. (5)\n\nEvery hospital performing transplant\nservices shall maintain written criteria for the selection of patients for such\nservices which shall be consistent with professional standards of practice, applied consistently, and made available to the public. (6)\n\nThe hospital shall maintain a record of: (i) all patients who are referred for\ntransplantation and the date of their referral; (ii)\nthe results of the evaluation of all\ncandidates for transplantation which documents the reasons a candidate is\ndetermined to be either suitable or unsuitable for transplantation; (iii)\nthe psychosocial evaluation; (iv)\nthe date a suitable candidate is\nselected for transplantation; (v) the reasons for, and date of, any declination of a matching organ or\nvascularized composite allograft offered to a potential recipient; (vi)\nthe date the transplantation surgery\noccurred; (vii)\ndocumentation of\ndonor and recipient blood type; (viii)\nthe donor's United Network for Organ\n\nSharing (UNOS) identification number; and\n(ix)\nthe organs or vascularized composite\nallografts utilized. (7)\n\nThe hospital will ensure that appropriate informed consent is obtained from\nboth the recipient and if applicable, the living donor. The process for\nobtaining such consent shall include the provision of information, at a minimum\nof the following: (i) the evaluation process\nused to determine suitability for transplant; (ii)\nthe surgical procedure including the\npost-operative period; (iii)\nthe\navailability of alternative treatments; (iv)\norgan donor risk factors that could\naffect the success of the graft or the health of the patient, including, but\nnot limited to, the donor's history, condition or age of the organs or\nvascularized composite allografts used, and the recipient's potential risk of\ncontracting the human immunodeficiency virus (HIV) and other infectious\ndiseases if the disease cannot be detected in an infected donor; (v) if applicable, providing adequate\ninformation to the recipient to ensure his or her understanding regarding the\nrisks to the living donor; (vi)\npotential medical and psychosocial risks; (vii)\nthe national and transplant center\noutcomes for recipients; (viii)\nthe\npatient's right to refuse transplantation, or the donor's right to refuse to be\na donor; and\n(ix)\nthe effect that\nprovision of transplant services provided in a facility not approved as a\n\nMedicare-approved transplant center could have on the recipient's ability to\nhave his or her immunosuppressive drugs paid for under Medicare Part\nB. (8)\n\nFor procedures\ninvolving a living donor, the hospital must obtain a written attestation from\nthe living donor attesting that the donor has not received anything of value in\nexchange for the donation, aside from reimbursement for expenses associated\nwith the donation to the extent allowed by New York State and Federal law. The\nrecipient must also attest in writing that he or she has not offered and is not\naware of any offers of valuable consideration to the donor for their donation, except as allowed by New York State or Federal law. (9)\n\nThe hospital must utilize an organized\nsystem for follow-up of patients after discharge, including maintenance of\nrecords on the long-term survival of persons who have received a transplant or\nwho have made a living donation. Transplant centers must follow the health of\neach donor for at least two years post-donation. (10)\n\nThe hospital shall ensure that written\nprocedures are maintained and implemented for the receipt, identification, and\nverification of all organs and vascularized composite allografts for\ntransplantation. (11)\n\nThe hospital\nshall develop, maintain and implement written infection control policies and\nprocedures specific to the transplant services, as an integral part of the\nhospital's infection control program. (12)\n\nThe hospital shall ensure that the\ninfection control program utilizes sufficient professional and laboratory\nresources to address transplant-related transmissible infections, including\ndiscovery, identification and management of complications from organisms\nassociated with transplants whether commonly or uncommonly\nencountered. (13)\n\nEach transplant\ncenter shall develop and implement a policy for a formalized process of\ncommunication with OPOs, the center's clinical staff, the department and as\nappropriate, local/city departments of health with regard to suspected and\nconfirmed donor disease transmission. This policy shall include: (i) identification of a patient safety\ncontact, with coverage so that there is a person available on a 24 hour, 7 days\na week, 365 days a year basis, to be the primary contact for possible disease\ntransmission events; (ii)\na\nprocedure to promptly contact the OPO that recovered the organ whenever a\nsuspected disease transmission has occurred; (iii)\nprompt communication and documentation\nwhen made aware of the suspected transmission; (iv)\nidentification of an infectious disease\nresource available to assist in the evaluation of a potential disease\ntransmission; and\n(v) the\ndocumentation of and notification to the transplant program director or his or\nher designee of the potential disease transmission, and the implementation of\nmechanisms to ensure that the information is acted upon in a timely\nmanner. (14)\n\nEvery\ntransplant center shall develop and implement a policy on travel for transplant\nincluding, transplant tourism, transplant commercialism and organ trafficking. Such policy may include: (i) notice to all\npotential donors and recipients of the legal prohibitions against the sale of\norgans or vascularized composite allografts; (ii)\ninformation about the medical risks of\nreceiving an organ or vascularized composite allografts in a foreign country, in particular, the risk of infectious disease transmission to and from the\nrecipient, the possible difficulties in obtaining recipient records related to\nthe surgical procedure and post-operative treatment, and in cases of living\ndonation the records regarding the donor's social/medical history; (iii)\nnotice that participation in transplant\ncommercialism and or organ trafficking may violate the laws of the countries\ninvolved as well as international treaties or conventions. (15)\n\nTransplant centers that provide liver\ntransplant services must join and be a member in good standing of a recognized\nconsortium organization providing quality assurance, peer review, data sharing, and best practices collaboration activities for liver transplant services. If\nsuch a consortium(s) exists for other transplant services, such as heart or\nkidney, transplant centers must join the appropriate organization relevant to\nthe transplants it performs and be a member in good standing. (16)\n\nReview. Facilities shall allow the\ndepartment, or its designee, to conduct site visits to and/or survey data and\npatient record reviews from existing and prospective new transplant\ncenters. (17)\n\nClosure. (i) Failure to meet one or more statutory or\nregulatory requirements or inactivity in a program for a period of 12 months\nmay result in actions up to and including withdrawal of approval as a\ntransplant center. (ii)\n\nVoluntary\nclosure. The hospital must provide a closure plan and written notification of\npotential closure to the department at least 60 days prior to planned\ndiscontinuance of transplant services. Such closure plan must address and\nprovide a means of implementation with regard to, at minimum, the following: the means by which the program's patients (including those being evaluated for\ntransplant, wait-listed patients, transplant recipients and living donors\ncurrently being treated by the program) will be provided with written notice of\nthe planned closure and the means by which such persons may transfer to another\ntransplant program; the means by which the Organ Procurement and Transplant\n\nNetwork, operated under contract with the U.S. Department of Health and Human\n\nServices by the United Network for Organ Sharing, the Federal Centers for\n\nMedicare and Medicaid Services and the hospital's transplant program's referral\nnetworks will be notified of the planned closure; and the means by which the\nprogram's patients (including those being evaluated for transplant, wait-listed\npatients, transplant recipients and living donors currently being treated by\nthe program) will be assisted in transferring to another transplant program. No\ntransplant service shall discontinue operation without prior written approval\nfrom the department. (18)\n\nNotification of significant changes. A\nhospital must notify the department in writing within seven days of any\nsignificant changes in its transplantation services including, but not limited\nto: (i) any temporary or permanent suspension\nof services; (ii)\ndeparture of or\nchange in the physician program director; (iii)\nunavailability of the transplant\nsurgeon or physician of more than 15 days, if a program is without a physician\ncredentialed to perform one or more of the procedures or services of the\ntransplant service as a result of such unavailability; or\n(iv)\ninability to meet workload\nrequirements. (19)\n\nData\ncollection and reporting. Data and governmental and accrediting body reports\nshall be maintained for a period at least as long as that required for the\nretention of patient medical records under this Part, and made available to the\ndepartment upon request. (c) Organization and staffing. (1)\n\nThe director of the transplant center, in\naddition to the requirements in section\n405.22\n(a)(1)\nof\nthis Part, shall be a qualified specialist with previous experience and\ndemonstrated competence in the transplant service. The director is responsible\nfor planning, organizing, conducting, and directing the transplant center and\nmust devote sufficient time to carry out these responsibilities including, but\nnot limited to overseeing the transplant center's quality assurance and\nperformance improvement (QAPI) program. (2)\n\nEach transplant center shall have on-site\na qualified transplant physician and another person who is a qualified\ntransplant surgeon who may also fulfill the requirement as director of the\nservice. (3)\n\nThe hospital shall\nprovide a clinical transplant coordinator and sufficient staff to coordinate\nthe activities of the transplant center, including patient follow-up after\ndischarge. The clinical transplant coordinator shall be a physician, registered\nprofessional nurse, registered physician assistant, or nurse practitioner, licensed and currently registered or certified to practice in New York\n\nState. (4)\n\nThe hospital shall\nensure that all staff members providing transplant services are prepared for\ntheir responsibilities through ongoing education, experience, demonstrated\ncompetence and completion of in-service education programs as needed. (5)\n\nFrom admission to discharge, including\npost discharge follow-up, patient care evaluation, planning and management\nshall be performed by a multidisciplinary care team involved with the care of\nthe patient; (which includes, at a minimum physicians, surgeons, nurses, qualified social workers, clinical transplant coordinators, nutritional\nservices as needed and pharmacy as needed). The patient and, as appropriate, the patient's family shall be involved and have input into the patient's care\nplan. (6)\n\nThe transplant center\nshall make available nutritional assessments and diet counseling services to\nall transplant recipients and donors. (7)\n\nThe transplant center shall make\npsychiatric and social services available, directly or via referrals, to\npatients to assist with psychosocial problems of the patients, as related to\nthe donation. Such professionals shall be skilled in individual and family\ncounseling, shall understand the entire donation and transplantation process, and be able to provide information on financial issues and community\nresources. (d) Quality assessment and performance improvement (QAPI) programs. (1)\n\nThe transplant center must develop, implement and maintain a written, comprehensive, data driven QAPI program to\nmonitor and evaluate performance of all transplantation services, including\nservices provided under contract or arrangement. (2)\n\nThe transplant center's QAPI program must\nuse objective measures to evaluate the center's performance with regard to\ntransplantation activities and outcomes. Outcome measures may include, but are\nnot limited to: patient and donor selection criteria, accuracy of the waiting\nlist in accordance with the Organ Procurement Transplantation Network (OPTN)\nwaiting list requirements, accuracy of donor and recipient matching, patient\nand donor management, techniques for organ and vascularized composite allograft\nrecovery, consent practices, patient education, patient satisfaction, and\npatient rights. (3)\n\nThe transplant\ncenter must take actions that result in ongoing performance improvements and\ntrack performance to ensure that improvements are sustained. (4)\nA transplant center must establish and\nimplement written policies to identify, analyze, report, address and document\nadverse events that occur during any phase of an organ or vascularized\ncomposite allograft transplantation case, and utilize such efforts to prevent\nfuture adverse events. (e) Organ and vascularized composite\nallograft acceptance criteria. (1)\n\nIn\nconsultation with an organ procurement organization, the hospital shall develop\nand uniformly apply organ and vascularized composite allograft acceptance\ncriteria and establish written policies and procedures to ensure the medical\nsuitability of organs and vascularized composite allografts to be transplanted. Hospitals shall also develop and uniformly apply acceptance criteria for living\ndonors. Such acceptance criteria shall be consistent with professional\nstandards of practice, and shall ensure that the living donor is at least 18\nyears of age at the time of the initial living donor evaluation. Specific\nmedical conditions of the donor shall be determined by the transplant surgeon\nthrough the donor's medical history, appropriate clinical laboratory testing\nand other confirmation methods and must be documented in the recipient's\nmedical record. A parent may consent to a living donation to the parent's own\nchild, regardless of the parent's age. (2)\n\nWritten organ and vascularized composite\nallograft acceptance criteria shall be: (i) specific for each type of organ or vascularized composite allograft; (ii)\nshall describe those medical conditions\nand circumstances which would make the potential donor ineligible; and\n(iii)\nshall describe those\nmedical conditions for which medical discretion may be exercised. (3)\n\nThe potential recipient will\nbe fully informed of the risks and benefits of the particular solid organ or\nvascularized composite allograft. Notes\nN.Y. Comp. Codes R. & Regs. Tit. 10\nยง\n405.30\n\nAmended by\n\nNew\n\nYork State Register September 10, 2014/Volume XXXVI, Issue 36, eff. 9/10/2014. Amended\n\nNew\n\nYork State Register November 13, 2019/Volume XLI, Issue 46, eff. 11/13/2019\n\nState regulations are updated quarterly; we currently have two versions available. Below is a\ncomparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare. No prior version found.",
  "url_type": "regulation",
  "source_index": 50020
}